Form 8-K · Current report
Charles River Laboratories 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001100682
- Accession no.
- 0001100682-26-000115
Summary
Charles River Laboratories reported second-quarter 2026 revenue of $1.00 billion, a GAAP loss per share of $(0.03), and non-GAAP earnings per share of $3.02, and it raised full-year 2026 revenue and non-GAAP EPS guidance while lowering GAAP EPS guidance due to divestiture-related losses.
Key points
- Second-quarter 2026 revenue was $1.00 billion, down 2.7% from $1.03 billion a year earlier, while organic revenue rose 0.1%.
- The company reported a GAAP net loss available to common shareholders of $1.5 million, or $(0.03) per diluted share, versus net income of $52.3 million, or $1.06 per diluted share, a year earlier, mainly due to a $63.7 million loss on the CDMO and Cell Solutions divestiture.
- Non-GAAP net income was $146.2 million and non-GAAP diluted EPS was $3.02, compared with $154.0 million and $3.12 a year earlier.
- Charles River raised its 2026 organic revenue growth guidance to 0.0%–1.0% and non-GAAP EPS guidance to $11.15–$11.45, while lowering GAAP EPS guidance to $3.05–$3.35, and repurchased $100 million of stock in the second quarter.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02. Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On August 5, 2026, Charles River Laboratories International, Inc. issued a press release providing financial results for the second quarter ended June 27, 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.